Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

Similar articles for PubMed (Select 18172172)

1.

Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.

Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J.

N Engl J Med. 2008 Jan 3;358(1):28-35. doi: 10.1056/NEJMoa070030.

2.

Factoring PAF in anaphylaxis.

Burks AW.

N Engl J Med. 2008 Jan 3;358(1):79-81. doi: 10.1056/NEJMe078159. No abstract available.

3.
4.

Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.

Bansal AS, Chee R, Sumar N.

N Engl J Med. 2008 Apr 3;358(14):1515-6 author reply 1516-7. No abstract available.

PMID:
18389523
5.

Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.

Okamoto H, Kamatani N.

N Engl J Med. 2008 Apr 3;358(14):1516; author reply 1516-7. No abstract available.

PMID:
18389524
6.

PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.

Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.

Nephrol Dial Transplant. 2006 May;21(5):1270-7. Epub 2006 Jan 18.

7.
8.

Anaphylaxis: clinical patterns, mediator release, and severity.

Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, Isbister GK.

J Allergy Clin Immunol. 2013 Nov;132(5):1141-1149.e5. doi: 10.1016/j.jaci.2013.06.015. Epub 2013 Aug 1.

PMID:
23915715
9.
11.

Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models.

Fukuda Y, Kawashima H, Saito K, Inomata N, Matsui M, Nakanishi T.

Eur J Pharmacol. 2000 Feb 25;390(1-2):203-7.

PMID:
10708725
12.

Platelet-activating factor, PAF acetylhydrolase, and anaphylaxis.

Levy JH.

N Engl J Med. 2008 Apr 3;358(14):1515; author reply 15167. doi: 10.1056/NEJMc080168. No abstract available.

13.

Plasma platelet-activating factor acetylhydrolase activity in critically ill patients.

Claus RA, Russwurm S, Dohrn B, Bauer M, Lösche W.

Crit Care Med. 2005 Jun;33(6):1416-9.

PMID:
15942364
15.

Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome.

Fan P, Liu HW, Wang XS, Zhang F, Song Q, Li Q, Wu HM, Bai H.

Hum Reprod. 2010 May;25(5):1288-94. doi: 10.1093/humrep/deq047. Epub 2010 Feb 25.

16.

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.

Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Böhm BO, März W.

Circulation. 2005 Mar 1;111(8):980-7. Epub 2005 Feb 14. Erratum in: Circulation. 2005 Jun 21;111(24):e444.

17.

Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.

Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.

Kidney Int. 1999 Dec;56(6):2276-85.

18.

Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese.

Unno N, Nakamura T, Mitsuoka H, Uchiyama T, Yamamoto N, Saito T, Sugatani J, Miwa M, Nakamura S.

Ann Surg. 2002 Feb;235(2):297-302.

19.

Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.

Dulioust A, Hilliquin P, Menkes CJ, Benveniste J, Arnoux B.

Scand J Rheumatol. 1992;21(4):161-4.

PMID:
1529281
20.

Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease.

Goudevenos J, Tselepis AD, Tsoukatos D, Grekas G, Kritikakos J, Sideris D.

Eur Heart J. 1995 Aug;16(8):1036-43.

PMID:
8665964
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk